NCT04594031 - US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease | Biotech Hunter

Timeline

Start Date

July 13, 2021

Primary Completion Date

September 1, 2023

Study Completion Date

February 2, 2024

Conditions

Sickle Cell DiseaseUmbilical Cord BloodHematopoietic Cell Proliferation

Interventions

BIOLOGICAL

ECT-001-CB (UM171-Expanded Cord Blood Transplant)

Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ \>1x10E6/kg)

Trial Locations (2)

University of California San Francisco, San Francisco

Stanford University School of Medicine, Palo Alto